This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.

Its that time of year again! Jade Teakell is leading team #UrineItToWinIt for #HCWvsHunger 2024. Read more.

This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.

This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?

Nausea is a very common and distressing problem. Some medications that treat nausea carry a higher risk for arrhythmias, like Torsades de Pointes, and sudden cardiac death. Is ondansetron safe for use in patients on hemodialysis?

This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?

This week is time antibody mediated rejection treatment in kidney transplant. A new molecule targeting CD38, on the horizon, safely tested in a phase 2 trial

This week, we will discuss the ongoing saga of blood pressure targets in patients with hypertension. This time its ESPRIT (Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing Risk of Vascular Events) making a case for case for intensive BP control in most hypertensive individuals, including those with a history of diabetes and stroke.

The NephJC Summer Book Club returns! We turn to fiction this time, 'The Covenant of Water', from Abraham Verghese.

This week, we will discuss an intriguing hypothesis for many nephrologists: can amino acids prevent acute kidney injury?

Is living kidney donation safe or does it bring hypertension and potential kidney badness on the horizon? This week we will be focusing on an encouraging JAMA article, hoping to be close to a more definitive answer

This week, we will discuss the RaDaR study. Does rare mean kidney failure occurs rarely? What are rare diseases? Do we see them in children more than adults? All this and more!

This week, we will maybe not expect the worse, while discussing the COMPASS post hoc analysis. Are PPIs so bad for the kidneys?

This week, we will discuss the blockbuster trial of 2024, FLOW. GLP1RAs have arrived in the nephrology realm.

This week, we will discuss the second part of the 2024 CKD guidelines from KDIGO. Lots to chew on, so let’s dive in!

This week, we will discuss the 2024 KDIGO Guidelines on CKD, part 1. In this section we will discuss the first two chapters on CKD evaluation and risk stratification. Let’s dive in!

This week, we will discuss the role of ApoE in determining the subtypes of C3 Glomerulopathy.

This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?

This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.

This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.

This week on NephTrials we will discuss the PROTECT-V trial, a platform trial for preventing COVID-19 infections in the vulnerable kidney populations.

This week, we will discuss the SLEEP-HD trial, which examined if trazodone or CBT are better than placebo in helping people sleep.

This week, we will discuss the recently published KDIGO lupus guidelines. Published a couple of years after the big GN guidelines - let us dive in to see what’s new in lupus nephritis

This week, we will be discussing a randomized controlled trial of eculizumab in STEC-HUS. Will eculizumab manage to surpass its well-established reputation as expensivumab and demonstrate some positive results?

2023 brought us has dogma shredding data on hyponatremia and the importance of different diuretics. It has new therapies for old diseases like IgA and hypertension. New drugs for new diseases like inaxaplin for AMKD. And it has new data on old debates like what IVF is best and do thiazides really prevent kidney stones. It is a great list. Dig in!

This week we will discuss the article from Lancet on the addition of an ASI to background RASi and empagliflozin. Did this work?

This week, the last 2023’ NephJC resurfaces an old dilemma, in a different SPACE- non-cardiac surgery. Should we STOP ACEi, or do we know better?

This week, we will discuss yet another endothelin antagonist trial, on a background of flozins, in proteinuric CKD. Will flozins help breakthrough the endothelin badness?

This week, we will discuss sparsentan again, but this time in FSGS. This is the largest FSGS trial ever. Will endothelin antagonists crack the sclerotic FSGS segment?

This week on #NephTrials, we will discuss platform trials, anchoring the discussion to the BEAT-Calci trial, which has a number of interesting design features.